Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder

• Published in: The Journal of neuroscience Vol. 41; no. 5; pp. 901 - 910
• Main Authors: Marvar, Paul J., Andero, Raül, Hurlemann, Rene, Lago, Tiffany R., Zelikowsky, Moriel, Dabrowska, Joanna
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 03.02.2021
• Subjects: Aggressive behavior; Angiotensin; Angiotensin II; Angiotensin receptors; Animals; Anxiety; Anxiety - drug therapy; Anxiety - metabolism; Anxiety - psychology; Defensive behavior; Drug therapy; Emotions - drug effects; Emotions - physiology; Extinction, Psychological - drug effects; Extinction, Psychological - physiology; Fear; Fear conditioning; Humans; Limbic System - drug effects; Limbic System - metabolism; Mental disorders; Modulators; Nerve Net - drug effects; Nerve Net - metabolism; Neuromodulation; Neuropeptides; Neuropeptides - metabolism; Neuropeptides - pharmacology; Neuropeptides - therapeutic use; Oxytocin; Oxytocin receptors; Post traumatic stress disorder; Psychological stress; Receptors; Receptors, Tachykinin - antagonists & inhibitors; Receptors, Tachykinin - metabolism; Signs and symptoms; Stress Disorders, Post-Traumatic - drug therapy; Stress Disorders, Post-Traumatic - metabolism; Stress Disorders, Post-Traumatic - psychology; Symposium/Mini-Symposium; Tachykinin; Tachykinin receptors; Tachykinins - antagonists & inhibitors; Tachykinins - metabolism; Trauma; Vasopressin; PTSD; anxiety; oxytocin; angiotensin II; vasopressin; tachykinin

Post-traumatic stress disorder (PTSD) is characterized by hypervigilance, increased reactivity to unpredictable versus predictable threat signals, deficits in fear extinction, and an inability to discriminate between threat and safety. First-line pharmacotherapies for psychiatric disorders have limi...